Evidence map›Paper›PMID 42604025›Full record

ReviewRegenerative therapy2026

Newborn screening and biobanking for preventable genetic disorders in Mongolia: A developing country perspective.

Khongorzul Batchuluun, Khishigjargal Batjargal, Altantuya Tsevgee, Altansuvd Enkhtur, Nurbyek Stipan, Elberelt Unurbat, Battogtokh Chimeddorj, Khurelbaatar Nyamdavaa, Damdindorj Boldbaatar, Erdenetuya Ganbaatar and 1 more

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Regenerative therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Khongorzul BatchuluunInstitute of Biomedical Sciences, Mongolian National University of Medical Sciences, Ulaanbaatar, 14210, Mongolia.
Khishigjargal BatjargalDepartment of Pediatrics, School of Medicine, Mongolian National University of Medical Sciences, Ulaanbaatar, 14210, Mongolia.
Altantuya TsevgeeDepartment of Pediatrics, School of Medicine, Mongolian National University of Medical Sciences, Ulaanbaatar, 14210, Mongolia.
Altansuvd EnkhturInstitute of Biomedical Sciences, Mongolian National University of Medical Sciences, Ulaanbaatar, 14210, Mongolia.
Nurbyek StipanInstitute of Biomedical Sciences, Mongolian National University of Medical Sciences, Ulaanbaatar, 14210, Mongolia.
Elberelt UnurbatInstitute of Biomedical Sciences, Mongolian National University of Medical Sciences, Ulaanbaatar, 14210, Mongolia.
Battogtokh ChimeddorjInstitute of Biomedical Sciences, Mongolian National University of Medical Sciences, Ulaanbaatar, 14210, Mongolia.
Khurelbaatar NyamdavaaDepartment of Physiology, School of Bio-Medicine, Mongolian National University of Medical Sciences, Ulaanbaatar, 14210, Mongolia.
Damdindorj BoldbaatarDepartment of Physiology, School of Bio-Medicine, Mongolian National University of Medical Sciences, Ulaanbaatar, 14210, Mongolia.
Erdenetuya GanbaatarDepartment of Pediatrics, School of Medicine, Mongolian National University of Medical Sciences, Ulaanbaatar, 14210, Mongolia.
Akihiro UmezawaNational Center for Child Health and Development Research Institute, Tokyo, 157-8535, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Newborn screening (NBS) is an important public health program, yet its implementation is highly uneven globally, with developing countries like Mongolia facing significant resource and infrastructure limitations that hinder early detection of preventable genetic disorders. Meanwhile, induced pluripotent stem cell (iPSC) technology, leveraged through biobanking, offers a powerful platform for disease modeling, drug discovery, and regenerative medicine, though its advanced applications are primarily concentrated in wealthier nations. We review the current status of NBS in Mongolia and argue for linking an expanded NBS program to an iPSC biobank. This link would improve diagnosis, create a foundation for Mongolian precision medicine, and strengthen local research capacity. We recognize the practical and ethical hurdles-funding, staffing, and data governance-and outline phased rollout, targeted training, and international partnerships as realistic next steps. Taken together, this approach could prevent avoidable disability in Mongolia while gradually building homegrown capability in genetic healthcare.

Identifiers

PMID42604025
PMCPMC13476635

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.